CONTENTS EXECUTIVE SUMMARY ............................................................................................................. 2 1 BACKGROUND ...................................................................

First Page		Document Content
Immunology Monoclonal antibodies Autoimmune diseases Arthritis Psoriasis Adalimumab Infliximab Anakinra Etanercept Medicine Immunosuppressants Pharmacology		CONTENTS EXECUTIVE SUMMARY ............................................................................................................. 2 1 BACKGROUND ................................................................... Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 232,48 KB Share Document on Facebook

	EAP Reimbursement Criteria for Frequently Requested Drugs DocID: 1rhhE - View Document
	UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol DocID: 1rakB - View Document
	RHEUMATOLOGY Rheumatology 2011;50:iv5iv9 doi:rheumatology/ker241 Indirect and mixed treatment comparisons in arthritis DocID: 1pLt5 - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GILOTRIF safely and effectively. See full prescribing information for GILOTRIF. ® DocID: 1oOLG - View Document
	------------------------DOSAGE AND ADMINISTRATION---------------------Rheumatoid Arthritis  Recommended dose of XELJANZ is 5 mg twice daily. (2.1)  Moderate and severe renal impairment and moderate hepatic impairme DocID: 1m0Le - View Document